StreetAlpha.app
Home › Stocks › LPCN

Lipocine Inc. (LPCN)

$1.62
▼ −2.41%
LAST CLOSE · NOV 17

Lipocine is a biopharmaceutical company that develops oral drugs, with its lead product TLANDO licensed to partners for testosterone therapy. It last closed at $1.62 on Nov 17, down 2.41% on the day.

AI Auto Pilots
Is LPCN in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$3.7M
−13.4% vs a year ago
Net income
−$9.3M
−249.2% margin
EPS (diluted)
−$1.28
Operating margin
−269.1%
−$10.1M operating income
Valuation
Market cap
$17.9M
11.1M shares
P/E
–
No P/E while losing money
Price to sales
4.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.6M
At Sep 30
Shareholder equity
$21.2M
Shares outstanding
11.1M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $16.1M$16.1MFY2021FY2022: $500K$500KFY2022FY2023: −$2.9M−$2.9MFY2023FY2024: $11.2M$11.2MFY2024FY2025: $2.0M$2.0MFY2025

From LPCN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated LPCN in the past 90 days, not enough for a consensus
Average 12-month target
$4.00
▲ 146.9% upside

Based on 1 analyst who set a price target on LPCN in the past 90 days. The average target is $4.00, with a high of $4.00 and a low of $4.00, compared with the last close of $1.62.

Low $4.00Avg $4.00High $4.00
Blue marker: last close $1.62
Highest target$4.00
Average target$4.00
Lowest target$4.00
Latest rating changes
HC Wainwright & Co.Reiterated
Sep 21Hold$4
DateFirmActionRatingPrice target
Sep 21HC Wainwright & Co.ReiteratedHold$4
Loading…

Technical Analysis

LPCN · as of the Nov 17 close · updated after every close
Downtrend

The stock sits between its 20 and 50 day averages. It is 110% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 48). The nearest support is the swing low (Oct 12) at $1.59, and the nearest resistance the Pivot R1 at $1.66.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 7.5%/day
Key levels
$12.3752 week high+663.6%
$3.40200 day average+109.9%
$2.03100 day average+25.3%
$1.8350 day average+13.0%
$1.73Swing high (Nov 9)+6.8%
$1.66Pivot R1+2.5%
$1.62Pivot+0.0%
$1.62Last close
$1.59Swing low (Oct 12)−1.9%
$1.57Pivot S1−3.1%
$1.5420 day average−4.9%
$1.3852 week low−14.8%
Indicators
RSI (14)48.00Middle of its rangeNeutral
MACD-0.04Above its signal lineBullish
Stochastic76.6Middle of its rangeNeutral
ADX (14)15.5No clear trend
Williams %R-35.1Oversold below −80, overbought above −20Neutral
CCI (20)68.5Oversold below −100, overbought above 100Neutral
Rate of change+11.0%Change over 10 sessionsBullish
ATR (14)$0.12Typical daily range, 7.5% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for LPCN

What happened before

See how LPCN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LPCN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LPCN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LPCN in the last 90 days.

Loading…

See today’s whale options flow across the market →

LPCN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼8 buying vs 10 selling
  • ▼Held by funds -0.8 pts
  • ▲Funds holding +1
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3837+2.7%
In funds' top 1000–
Held by funds26.1%26.9%−0.8 pts
New / increased2 / 65 / 14−57.9%
Reduced / sold out9 / 13 / 15−44.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LPCN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LPCN is in one of them and how their past LPCN trades turned out.

LPCN in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LPCN in an article yet. Here's the latest on the wider market.

About Lipocine

Lipocine is a biopharmaceutical company based in Salt Lake City, United States. It uses its own technology to develop medicines taken by mouth, including drugs that the body does not absorb well in standard form. Its lead product, TLANDO, is an oral treatment for testosterone deficiency in adult men, and partner companies sell it to patients in several countries. The company also develops candidates for brain and nervous system conditions, liver disease, and hormone treatments.

Headquarters
Salt Lake City